
Sampre Nutritions (SAMPRE) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
108.6M
Gross Profit
68.9M
63.47%
Operating Income
9.8M
9.03%
Net Income
7.1M
6.52%
EPS (Diluted)
₹0.34
Balance Sheet Metrics
Total Assets
1.2B
Total Liabilities
245.6M
Shareholders Equity
908.8M
Debt to Equity
0.27
Cash Flow Metrics
Revenue & Profitability Trend
Sampre Nutritions Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 251.2M | 251.5M | 371.1M | 231.3M | 182.3M |
Cost of Goods Sold | 83.6M | 165.7M | 286.3M | 166.8M | 118.5M |
Gross Profit | 167.6M | 85.8M | 84.8M | 64.5M | 63.8M |
Gross Margin % | 66.7% | 34.1% | 22.9% | 27.9% | 35.0% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 7.0M | 8.8M | 5.3M | 6.1M |
Other Operating Expenses | 98.2M | 8.9M | 11.9M | 4.9M | 5.8M |
Total Operating Expenses | 98.2M | 15.9M | 20.7M | 10.2M | 11.9M |
Operating Income | -58.3M | 22.9M | 22.3M | 18.8M | 16.2M |
Operating Margin % | -23.2% | 9.1% | 6.0% | 8.1% | 8.9% |
Non-Operating Items | |||||
Interest Income | - | 375.0K | 17.0K | 37.0K | 6.0K |
Interest Expense | 20.7M | 19.0M | 17.8M | 17.2M | 15.3M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | -75.2M | 4.9M | 4.2M | 3.7M | 1.1M |
Income Tax | 1.5M | 2.6M | 703.0K | 644.0K | 329.0K |
Effective Tax Rate % | 0.0% | 52.5% | 16.8% | 17.3% | 30.3% |
Net Income | -76.7M | 2.3M | 3.5M | 3.1M | 757.0K |
Net Margin % | -30.5% | 0.9% | 0.9% | 1.3% | 0.4% |
Key Metrics | |||||
EBITDA | -34.9M | 42.2M | 40.2M | 37.5M | 34.5M |
EPS (Basic) | ₹-3.65 | ₹0.34 | ₹0.61 | ₹0.64 | ₹0.16 |
EPS (Diluted) | ₹-5.43 | ₹0.34 | ₹0.61 | ₹0.64 | ₹0.16 |
Basic Shares Outstanding | 21020000 | 6870000 | 5729863 | 4820000 | 4820000 |
Diluted Shares Outstanding | 21020000 | 6870000 | 5729863 | 4820000 | 4820000 |
Income Statement Trend
Sampre Nutritions Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 2.3M | 2.8M | 1.0M | 593.0K | 746.0K |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 88.5M | 67.2M | 74.7M | 59.7M | 62.2M |
Inventory | 57.1M | 75.8M | 70.4M | 70.9M | 72.9M |
Other Current Assets | - | 1.0K | - | - | -1.0K |
Total Current Assets | 154.7M | 159.4M | 163.6M | 143.6M | 142.4M |
Non-Current Assets | |||||
Property, Plant & Equipment | 198.6M | 27.3M | 27.1M | 25.7M | 23.8M |
Goodwill | 0 | 0 | 0 | 0 | - |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | - | 8.7M | 1.4M | 1.2M | -1 |
Total Non-Current Assets | 999.6M | 288.1M | 272.3M | 233.4M | 240.5M |
Total Assets | 1.2B | 447.5M | 435.9M | 377.0M | 382.9M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 45.6M | 20.6M | 38.4M | 38.1M | 48.4M |
Short-term Debt | 63.2M | 80.1M | 60.3M | 84.7M | 90.1M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 23.3M | 11.6M | 6.5M | 296.0K | 546.0K |
Total Current Liabilities | 132.2M | 121.9M | 112.1M | 133.4M | 147.9M |
Non-Current Liabilities | |||||
Long-term Debt | 105.8M | 94.9M | 107.4M | 127.6M | 122.1M |
Deferred Tax Liabilities | 7.6M | 6.1M | 4.8M | 5.1M | 5.1M |
Other Non-Current Liabilities | - | - | - | - | -1 |
Total Non-Current Liabilities | 113.4M | 101.0M | 112.2M | 132.7M | 127.2M |
Total Liabilities | 245.6M | 222.8M | 224.3M | 266.1M | 275.0M |
Equity | |||||
Common Stock | 210.1M | 72.7M | 68.7M | 48.2M | 48.2M |
Retained Earnings | - | 64.8M | 62.5M | 59.0M | 55.9M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 908.8M | 224.7M | 211.6M | 110.9M | 107.8M |
Key Metrics | |||||
Total Debt | 169.0M | 175.0M | 167.7M | 212.3M | 212.2M |
Working Capital | 22.6M | 37.6M | 51.5M | 10.2M | -5.5M |
Balance Sheet Composition
Sampre Nutritions Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -75.2M | 4.9M | 4.2M | 3.7M | 1.1M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | 17.9M | -4.8M | -28.8M | -9.5M | -26.3M |
Operating Cash Flow | -42.8M | 19.0M | -6.8M | 11.0M | -17.8M |
Investing Activities | |||||
Capital Expenditures | -2.8M | -37.0M | -43.2M | -7.7M | -9.0M |
Acquisitions | -714.6M | 0 | 0 | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -717.4M | -37.1M | -43.2M | -7.7M | -9.0M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | -16.9M | - | -24.4M | -5.4M | - |
Financing Cash Flow | 739.4M | 30.6M | 48.4M | -10.8M | 2.5M |
Free Cash Flow | -1.9M | 2.4M | -35.3M | 11.1M | -25.3M |
Net Change in Cash | -20.8M | 12.6M | -1.6M | -7.6M | -24.3M |
Cash Flow Trend
Sampre Nutritions Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
151.31
Price to Book
1.40
Price to Sales
4.06
PEG Ratio
-0.13
Profitability Ratios
Profit Margin
-22.45%
Operating Margin
9.03%
Return on Equity
-8.44%
Return on Assets
-6.65%
Financial Health
Current Ratio
1.17
Debt to Equity
18.60
Beta
-0.34
Per Share Data
EPS (TTM)
₹-5.20
Book Value per Share
₹43.25
Revenue per Share
₹13.13
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
sampre | 1.3B | 151.31 | 1.40 | -8.44% | -22.45% | 18.60 |
Balrampur Chini | 110.1B | 25.28 | 2.90 | 12.14% | 8.07% | 69.21 |
Triveni Engineering | 73.8B | 34.85 | 2.32 | 7.70% | 3.61% | 62.67 |
Bannari Amman Sugars | 47.3B | 41.67 | 2.66 | 6.04% | 5.77% | 8.43 |
Bajaj Hindusthan | 29.0B | - | 0.67 | -0.35% | -0.42% | 84.48 |
Dalmia Bharat Sugar | 28.6B | 7.40 | 0.88 | 11.96% | 9.93% | 32.28 |
Financial data is updated regularly. All figures are in the company's reporting currency.